Home > SS>

Dr. Mary Sue Brady

Memorial Sloan-Kettering Cancer Center


Email: bradym@mskcc.org


1983 M.D., University of Miami

1978 B.Sc., University of Colorado

Publications (selected)

  1. Brady MS, Weinberg H, Kraus D, Lewis JJ, Coit DG, and Busam K. Lymphatic mapping in the management of melanoma in children. Ped Dermatol 1999;15(6):421-425.
  2. Saenz N, Saenz, Badillos J, Busam K, La Quaglia M, and Brady MS. Survival in childhood melanoma Survival. Cancer 1999;85:750-4.
  3. Brady MS, Eckels, DD, Lee F, Ree S, and Lee, JS. Cytokine production by CD4+ T cells responding to antigen presentation by melanoma. Melanoma Res 1999;9:173-80.
  4. Hill ADK, Brady MS, Coit DG. Intra-operative lymphatic mapping and sentinel lymph node biopsy for merkel cell carcinoma. Br J Surg. 1999;86:518?21.
  5. Nguyen AT, Akhurst T, Larson SM, Coit DG, and Brady MS. PET scanning with 18F 2-Flouro-2-deoxy-d-glucose (FDG) in patients with melanoma: benefits and limitations. Clin Positron Imag 1999;2:93-98.
  6. Busam KJ, Woodruff JM, Erlandson R, and Brady MS. Large plaque type blue nevus with subcutaneous cellular nodules. Am J Surgical Pathol 2000;24:92-9.
  7. Brady MS, Lee F, Eckels DD, Ree SY, Latouche J-B, and Lee JS. Restoration of alloreactivity of melanoma by transduction with B7.1. J Immunother 2000;23:353-61.
  8. Brady MS, Lee F, Petrie H, Eckels DD, Lee JS. CD4+ T Cells kill HLA class II positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 2000;48: 621-626.
  9. Saenz-Badillos J, Brady MS. Pregnancy associated melanoma occurring in two generations. J Surg Oncol. 2000;73:231-3.
  10. Brady MS, Oliveria SA, Christos PJ, Berwick M, Coit DG, Katz J, Halpern AC. Patterns of detection in cutaneous melanoma-implications for secondary prevention. Cancer 2000;89(2):342-7.
  11. Hoos A, Berho M, Blumencranz PW, Schaefer GD, and Brady MS. Giant cellular blue nevus of the anterior chest wall mimicking metastatic melanoma to the breast. J Surg Oncol 2000 74(4):278-81.
  12. Clary BM, Brady MS, Lewis JJ, and Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250-8.
  13. Clary BM, Mann B, Brady MS, Lewis JJ, and Coit DG. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001;8:328-37.
  14. Mahabir S, Coit D, Liebes L, Brady MS, Lewis JJ, Roush G, Nestle M, Fay D, and Berwick M. Randomized, placebo-controlled trial of dietary supplementation of a-tocopherol on mutagen sensitivity levels in melanoma patients: a pilot trial. Melanoma Research, 2002, 12: 83-90.
  15. Nguyen AT, Kavolius JP, Russo P, Grimaldi, G, Katz J, and Brady MS. Primary genitourinary melanoma. Urology 2001;57:633-8.
  16. Berwick M, Song Y, Jordan R, Brady MS, Orlow I. Mutagen sensitivity as an indicator of soft tissue sarcoma risk. Environ Mol Mutagen 38:223-226, 2001.
  17. Lohmann CM, Coit D, Brady MS, and Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial Spitzoid melanocytic tumors. Am J Surg Path 2002:26:47-55.
  18. Patel SG, Coit DG, Shaha AR, Brady MS, Boyle JO, Singh B, Shah JP, Kraus DH. Sentinel lymph node biopsy for cutaneous head and neck melanomas. Arch Otolaryngol Head Neck Surg 2002; 128(3):285-91.
  19. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit D. Multivariate prognostic model for patients with thick cutaneous melanoma; importance of sentinel lymph node status. Ann Surg Oncol 2002;45(7):637-45.
  20. Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003;10:27-31.
  21. Gyorki DE, Busam K, Panageas K, Brady MS, and Coit DG. Sentinel Lymph Node Biopsy for Patients with Cutaneous Desmoplastic Melanoma. Ann Surg Oncol 2003 10(4):403-7.
  22. Negin BP, Riedel E, Oliveria S, Coit DG, Brady MS. Symptoms and signs of primary melanoma: an important indicator of Breslow depth. Cancer 2003;98(2):344-8.
  23. Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady MS, et al. Estimating the relative risk of developing melanoma in INK4A carriers. Eur J Cancer Prev 2004;13: 65-70.
  24. Busam KJ, Mujumdar U, Hummer A, Nobrega J, Hawkins W, Coit D, and Brady MS. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol  2004;11:1518-25.
  25. Mahabir S, Frenkel K, Brady MS, Coit D, Leibes L, Karkoszka J, and Berwick M. Randomized, placebo-controlled pilot trial of the effects of a-tocopherol supplementation on levels of autoantibodies against 5-hydroxymethyl-2-deoxyuridine in melanoma patients. Mel Research 2004;14:49-56.
  26. Brady MS. Sentinel lymph node mapping in patients with cutaneous melanoma.   Dermatol Surg 2004;30:266-272.
  27. Brady MS. Current management of patients with Merkel cell carcinoma. Dermatol Surg 2004;30:273-277.
  28. Jimenez R, Panageas K, Busam K, Brady MS. Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. J Clin Oncol 2005; 23:518-24.
  29. Hawkins WG, Busam KJ, Ben-Porat L, Panageas K, Coit DG, Gyorki DE, Linehan DC, and Brady MS. Desmoplastic Melanoma:a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005;12(3):207-13.
  30. Clausen SP, Brady MS. Surgical margins in patients with cutaneous melanoma-assessing the adequacy of excision. Melanoma Res 2005 (6):539-42.
  31. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006;13(3):302-9.
  32. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, Larson S. Utility of Preoperative [(18)]F Fluorodeoxyglucose-Positron Emission Tomography Scanning in High-Risk Melanoma Patients. Ann Surg Oncol 2006;13(4):525-32.
  33. Bero SM, Busam KJ, Brady MS. Cutaneous melanoma arising in a burn scar: two recent cases and a review of the literature. Melanoma Res 2006(1):71-6.
  34. Picon AI, Coit DG, Shaha AR, Brady MS, Boyle JO, Singh BB, Wong RJ, Busam KJ, Shah JP, Kraus DH.Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland. Ann Surg Oncol. 2006 May 23; [Epub ahead of print].
  35. Brady MS, Brown K, Patel A, Fisher C, and Marx W. A Phase II Trial of Isolated Limb Infusion with Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity. Ann Surg Oncology 13:1123-1129, 2006.
  36. Bero SM, Brady MS. Streptococcal septic shock after inguinal lymphadenectomy. Surg Infect 2006;7:547-50.
  37. Dalal KM, Patel A, Brady MS, Jaques DP, Coit DG. Patterns of First Recurrence and Post-recurrence Survival in Patients with Primary Cutaneous Melanoma after Sentinel Lymph Node Biopsy.Ann Surg Oncol. 2007 Jun;14(6):1934-42.
  38. Taylor RC, Patel A, Panageas KS, Busam KJ, and Brady MS. Tumor Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma. J Clin Oncol 25: 869-75, 2007.
  39. Gold J, Jaques DP, Busam KJ, Brady MS, and Coit DG. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncology 2007;14:2133-40.
  40. Cohen T, Busam K, Patel A, and Brady MS. Subungual melanoma: management   considerations. Am J Surg 2008;195(2):244-8.
  41. Hay J, Shuk E, Brady MS, Berwick M, Ostroff J, and Halpern A. Family communication after melanoma diagnosis. Arch Dermatol. 2008 Apr;144(4):553-4.